The role of intestinal alkaline phosphatase in the development of necrotizing enterocolitis

Early Hum Dev. 2023 Aug:183:105797. doi: 10.1016/j.earlhumdev.2023.105797. Epub 2023 Jun 7.

Abstract

Necrotizing enterocolitis (NEC) is a devastating neonatal disease that affects neonates worldwide and often leads to high morbidity and mortality rates. Despite extensive research, the cause of NEC remains unclear, and current treatment options are limited. An important novel finding is the potential role of intestinal Alkaline Phosphatase (IAP) in both pathogenesis and treatment of NEC. IAP can play a vital role in detoxifying liposaccharides (LPS), a key mediator of many pathological processes, thereby reducing the inflammatory response associated with NEC. Furthermore, IAP can help prevent dysbiosis, improve intestinal perfusion, and promote autophagy. In this comprehensive review, we present evidence of the possible connection between IAP and the LPS/Toll-like receptor 4 (TLR4) pathway, impaired gut immunity, and dysbiosis in the preterm gut. Based on these findings, the administration of exogenous IAP might provide promising preventive and therapeutic avenues for the management of NEC.

Keywords: Intestinal alkaline phosphatase; Liposaccharides; Necrotizing enterocolitis; Prematurity; Toll-like receptor 4.

Publication types

  • Review

MeSH terms

  • Alkaline Phosphatase / metabolism
  • Alkaline Phosphatase / therapeutic use
  • Dysbiosis / drug therapy
  • Enterocolitis, Necrotizing* / drug therapy
  • Humans
  • Infant, Newborn
  • Infant, Newborn, Diseases* / drug therapy
  • Lipopolysaccharides / therapeutic use

Substances

  • Alkaline Phosphatase
  • Lipopolysaccharides